Table 3. Different expert guidelines recommend the use of multigenic assays.
| Multigenetic assay | ASCO | NCCN | St. Gallen | EGTM |
|---|---|---|---|---|
| Oncotype Dx | pN0 | pN0; pN1 (1–3 positive nodes) | pN0; pN1 (1–3 positive nodes) | pN0; pN1 (1–3 positive nodes) |
| Mammaprint | Not determined | Not determined | pN0; pN1 (1–3 positive nodes) | pN0; pN1 (1–3 positive nodes) |
| Endopredict | pN0 | Not determined | pN0; pN1 (1–3 positive nodes) | pN0; pN1 (1–3 positive nodes) |
| PAM50 | pN0 | Not determined | pN0; pN1 (1–3 positive nodes) | pN0; pN1 (1–3 positive nodes) |
| BCI | pN0 | Not determined | pN0; pN1 (1–3 positive nodes) | pN0 |
ASCO, American Society of Clinical Oncology; NCCN, National Comprehensive Cancer Network; EGTM, European Organization Tumor markers; PAM50, mRNA expression of 50 genes; BCI, breast cancer index.